zurück

Axicabtagen-Ciloleucel (re-assessment: diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), ≥ 2 prior therapies)


Subject:

  • Active Substance: Axicabtagen-Ciloleucel
  • Name: Yescarta®
  • Therapeutic area: diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL)
  • Pharmaceutical company: Gilead Sciences GmbH


Time table:

  • Start: 15.05.2022
  • Final decision by G-BA: 03.11.2022


Final decision:

  1. Adult patients with DLBCL after two or more systemic therapies: Hint for a non-quantifiable additional benefit
  2. Adult patients with PMBCL after two or more systemic therapies: Hint for a non-quantifiable additional benefit